As these early changes suggested acceleration of metabolic-associated fatty liver disease towards advanced liver disease in response to shChREBP, we next evaluated the hepatic effects of prolonged normalized ChREBP activity in L-G6pc−/− mice (Fig. S2A). Here, MLXIPL is linked to fatty liver disease.